22:23 , Apr 6, 2017 |  BC Innovations  |  Targets & Mechanisms

Competing for growth

With little in the clinical pipeline for achondroplasia beyond BioMarin Pharmaceutical Inc.’s late-stage vosoritide, startups Therachon AG and BioClin Therapeutics Inc. are rethinking how to tackle the disease. By targeting FGFR3 directly, the two companies...
21:00 , Mar 22, 2017 |  BC Extra  |  Financial News

BioClin raises $30M in series B

Antibody company BioClin Therapeutics Inc. (San Ramon, Calif.) raised $30 million in a series B round led by new investors Sofinnova Ventures and Ysios Capital. Existing investors HealthCap, LSP and Tekla Capital Management also participated. The...
07:00 , Oct 5, 2015 |  BC Week In Review  |  Clinical News

B-701: Phase II started

BioClin began a double-blind, placebo-controlled, U.S. Phase II trial to compare 25 mg/kg IV B-701 with docetaxel on day 1 of each 21-day cycle vs. docetaxel alone in about 211 patients with stage IV disease...